近年来,胰高血糖素样肽-1受体激动剂(GLP-1 RA)和钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)在减少蛋白尿、延缓血清肌酐翻倍率和推迟ESKD进展方面显示出了效果【1】。 2024年11月6日,Ming-Hsien Tsai等研究学者在期刊Journal of ...
Introduction: Euglycemic diabetic ketoacidosis (DKA) is a known adverse effect associated with the use of SGLT2 inhibitors. The concomitant initiation of GLP1 agonists with SGLT2 inhibitors presents a potential synergistic risk, precipitating metabolic acidosis without significant hyperglycemia. The ...
CV, cardiovascular; GLP-1RA, glucagon-like peptide-1 receptor agonist; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; MI, myocardial infarction; SGLT2i, sodium-glucose cotransporter 2 inhibitor....
Few studies explored the effect of the combination of glucose sodium-cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on the incidence of cardiovascular events in patients with type 2 diabetes (T2D) and acute myocardial infarction (AMI). Methods We re...
upon these findings, we conducted this longitudinal investigation using an extensive global medical records database to explore the associations between GLP-1 RAs and mortality, adverse cardiovascular and kidney-related events in a substantial cohort of individuals with type 2 diabetes concomitant with ...
ADM indicates antidiabetic medication; DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide-1; SGLT2, sodium-glucose cotransporter 2. Table 1. Selected Characteristics of Pregnant Women With Pregestational Type 2 Diabetes and Periconceptional Use of Second-Line Antidiabetic Medicationa View...
and the concomitant inhibition of glucagon secretion by alpha-cells. GLP-1 RAs do not only act on insulin secretion but also have a wide spectrum of pleotropic action that is reported in Fig.1. In particular, they have shown a reduction of major adverse cardiovascular events (MACE) in ...
(RCTs) showed the cardioprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose-like transport-2 inhibitors (SGLT-2i) in T2DM patients, but most of the participants were men. It is not known whether these newer diabetes medications are equally beneficial ...
In PIONEER 2, RYBELSUS®went head-to-head against the most prescribed SGLT-2i with mean change in A1C from baseline to 26 weeks as a primary endpoint and mean change in body weight from baseline to 26 weeks as a confirmatory secondary endpoint.1,3,4 ...
Pierre Gourdy1,2*, Patrice Darmon3, François Dievart4, Jean‑Michel Halimi5,6 and Bruno Guerci7 Abstract Due to their cardiovascular protective effect, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glu‑ cose cotransporter-2 inhibitors (SGLT2is) rep...